Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are comparing two surgical techniques for placing a total knee replacement in patients with advanced knee osteoarthritis. The study evaluates image-based robotic total knee arthroplasty and imageless augmented reality-assisted total knee arthroplasty. Both techniques aim to improve the accuracy of prosthesis placement using additional angle and axis information obtained during surgery. This comparison seeks to determine if the two methods provide equivalent results and optimize patient care. Participants will undergo one of two procedures the Skywalker Robotics Assisted TKA using the Evolution Medial Pivot Knee or the Pixee Knee augmented reality-assisted TKA using the same knee prosthesis. Both are established surgical methods that use technology to guide precise implant positioning. The study randomly assigns patients to either surgical technique to assess and compare their effectiveness. During the study, researchers will monitor implant alignment and positioning via full-leg standing X-rays for one year after surgery. They will also assess safety, clinical outcomes, and activity levels over a two-year follow-up period. Participants will have regular assessments to track recovery, implant function, and overall knee performance, contributing to a better understanding of these assistive technologies in knee replacement surgery.
Actively Recruiting
Researchers are evaluating the efficacy and safety of Eloralintide LY3841136 for adults with osteoarthritis of the knee who are overweight or obese and experiencing knee pain. This Phase 3, randomized, double-blind, placebo-controlled study aims to assess how well Eloralintide works in reducing body weight and improving knee pain. The trial is sponsored by Eli Lilly and Company and includes two independent studies under a master protocol. Participants will receive once-weekly subcutaneous injections of either Eloralintide or placebo. The study includes parallel treatment arms comparing Eloralintide to placebo in adults with osteoarthritis knee pain and weight concerns. Treatment lasts for approximately 64 weeks, with dosing and assessments occurring regularly. The study also allows for a total participation duration of about 75 weeks, including screening. During the trial, participants will undergo various assessments including measurements of body weight, knee pain using the Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale, physical function, blood pressure, inflammatory markers, and walking distance. Researchers will monitor medication use and collect data on quality of life and biochemical markers. Safety and pharmacokinetics of Eloralintide are also tracked throughout the study.